Take Action

Home | Faculty & Research Overview | Research

Research Details

Vioxx: Too Risky for Merck?

Abstract

This case follows Merck's pharmaceutical product, Vioxx, from initial development to launch and subsequent withdrawal, and considers the decisions made at each stage by the Merck executives involved. The case concludes by examining the financial impact of the Vioxx withdrawal on the company and on the Merck stock value. 

Type

Case

Author(s)

Mitchell A. Petersen, Rashmi Singhal

Date Published

06/12/2018

Citations

Petersen, A. Mitchell, and Rashmi Singhal. Vioxx: Too Risky for Merck?. Case 5-207-253 (KEL289).

KELLOGG INSIGHT

Explore leading research and ideas

Find articles, podcast episodes, and videos that spark ideas in lifelong learners, and inspire those looking to advance in their careers.
learn more

COURSE CATALOG

Review Courses & Schedules

Access information about specific courses and their schedules by viewing the interactive course scheduler tool.
LEARN MORE

DEGREE PROGRAMS

Discover the path to your goals

Whether you choose our Full-Time, Part-Time or Executive MBA program, you’ll enjoy the same unparalleled education, exceptional faculty and distinctive culture.
learn more

Take Action